We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Swiss-licensed medical cannabis producer, swisscann, targets the expansive €12 billion global medical cannabis market, with an EU distribution agreement already secured. Leveraging its THC-licensed production facility, the company aims to meet the rising demand for safe and effective medical cannabis products, boasting a cultivation license and a partnership with a publicly listed European pharmaceutical distributor. Strategically headquartered in Zurich, Switzerland, swisscann benefits from proximity to Germany, Europe's largest medical cannabis market projected to reach multibillion-Euro valuations by 2027. Anticipating availability in European pharmacies and an initial launch in the German market by Q1 2024, swisscann aims to establish its foothold in the European medical cannabis landscape.
days to go: Expired investment: £1,067,294
Please watch the video for more information
days to go: Expired investment: £360,250
Cellmed is an immuno-oncology company that are developing treatments for ovarian cancer.  Their lead product PROCURE a dendritic cell vaccine and they are now looking to expand the treatment to target solid tumors.    
days to go: Expired investment: £520,294
Combat Medical have created an innovative method to treat bladder cancer by using heated chemotherapy. By heating the treatment the membrane is more permeable and is able to penetrate further. 
days to go: Expired investment: £1,725,220
Please watch the video for more information
days to go: Expired investment: £328,193
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph